Table 3.
Initial treatment efficacy and long-term therapeutic data
| Initial treatment efficacy | Treatment received after leaving the ICU | ||||
|---|---|---|---|---|---|
| n = 20 | n = 18 | ||||
| At 3 months | At 1 year | At 2 years | |||
| Treatment | n | Efficacy | n (%) | n (%) | n (%) |
| Corticosteroids alone | 20 | 10 (50%) | 4/18 (22%) | 3/18 (17%) | 3/13 (23%) |
| IVIgs | 6 | 1 (17%) | 1/18 (5%) | 0 | 0 |
| Cyclosporine | 3 | 1 (33%) | 3/18 (17%) | 2/18 (11%) | 0 |
| Anakinra (IL1Ra) | 5 | 4 (80%) | 10/18 (56%) | 7/18 (39%) | 3/13 (23%) |
| Etoposide | 3 | 2 (67%) | 0 | 0 | 0 |
| Methotrexate | 5/18 (28%) | 5/18 (28%) | 4/13 (31%) | ||
| Leflunomide | 1/18 (5%) | 0 | 0 | ||
| TNF-α blockers | 1/18 (5%) | 1/18 (5%) | 1/13 (7%) | ||
| Cyclophosphamide | 0 | 1/18 (5%) | 1/13 (7%) | ||
| Azathioprine | 0 | 1/18 (5%) | 1/13 (7%) | ||
| Tocilizumab (anti-IL6) | 0 | 1/18 (5%) | 0 | ||
| Remission off treatment | 0 | 2/18 (5%) | 3/13 (23%) | ||
ICU intensive care unit, IL1Ra interleukin-1 receptor antagonist, IVIgs intravenous immunoglobulins, TNF tumour necrosis factor